Symbol="CYCN"
AssetType="Common Stock"
Name="Cyclerion Therapeutics Inc"
Description="Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts."
CIK="1755237"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="301 BINNEY STREET, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="7921700"
EBITDA="-29207500"
PERatio="None"
PEGRatio="None"
BookValue="2.139"
DividendPerShare="0"
DividendYield="0"
EPS="-16.7"
RevenuePerShareTTM="0.276"
ProfitMargin="0"
OperatingMarginTTM="-48.09"
ReturnOnAssetsTTM="-0.807"
ReturnOnEquityTTM="-1.891"
RevenueTTM="608000"
GrossProfitTTM="-29749000"
DilutedEPSTTM="-16.7"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.141"
AnalystTargetPrice="4"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="17.43"
PriceToBookRatio="1.711"
EVToRevenue="0.517"
EVToEBITDA="0.529"
Beta="1.855"
num_52WeekHigh="25"
num_52WeekLow="2.767"
num_50DayMovingAverage="4.012"
num_200DayMovingAverage="9.07"
SharesOutstanding="2407800"
DividendDate="None"
ExDividendDate="None"
symbol="CYCN"
open="3.11"
high="3.29"
low="3.00"
price="3.29"
volume="16654.00"
latest_trading_day="2023-08-03"
previous_close="3.18"
change="0.11"
change_percent="3.4591%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="92"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="8"
Volume_recent_avg="197567"
Change_recent_avg="0.01"
Delta_recent_avg="0.22"
Variance_recent_avg="0.11"
Change_ratio_recent_avg="-1.03"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="8"
Aroon_momentum_negative="92"
image_negative_thumbnail_id_1="1117"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0150.jpeg"
image_negative_thumbnail_id_2="161"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0015.jpeg"
image_neutral_thumbnail_id_1="538"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0061.jpeg"
image_neutral_thumbnail_id_2="534"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0065.jpeg"
image_positive_thumbnail_id_1="647"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0061.jpeg"
image_positive_thumbnail_id_2="991"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0153.jpeg"
image_professor_thumbnail_id_1="1185"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0019.jpeg"
image_professor_thumbnail_id_2="1188"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0022.jpeg"
